Two-year cost effectiveness between two gradual tapering strategies in rheumatoid arthritis: cost-utility analysis of the TARA trial

OBJECTIVE: The aim of the current study was to evaluate the 2-year cost-utility ratio between tapering conventional synthetic disease-modifying antirheumatic drugs (csDMARD) first followed by the tumour necrosis factor (TNF)-inhibitor, or vice versa, in patients with rheumatoid arthritis (RA). METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: van Mulligen, Elise, Weel, Angelique E, Kuijper, Tjallingius Martijn, Denissen, N H A M, Gerards, Andreas H, de Jager, Mike H, Lam-Tse, Wai-Kwan, Hazes, J M, van der Helm-van Mil, Annette, de Jong, Pascal Hendrik Pieter, Luime, Jolanda J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677489/
https://www.ncbi.nlm.nih.gov/pubmed/32907801
http://dx.doi.org/10.1136/annrheumdis-2020-217528

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677489/
https://www.ncbi.nlm.nih.gov/pubmed/32907801
http://dx.doi.org/10.1136/annrheumdis-2020-217528

Ejemplares similares